Jaume Pons

Pfizer (United States) — United States

Immunology and Microbiology · Life Sciences

17h-index1.5kcitations30works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phagocytosis and Immune Regulation(17), Immunotherapy and Immune Responses(11), Monoclonal and Polyclonal Antibodies Research(11), Cancer Immunotherapy and Biomarkers(5), Glycosylation and Glycoproteins Research(4)

Publications30 total

Epitope Mapping Using Yeast Display and Next Generation Sequencing
Methods in molecular biology·2025
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication
Nature Medicine·2022· 240 citedOpen Access
Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)
Blood·2021· 15 cited
780 ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity
Regular and Young Investigator Award Abstracts·2021· 4 citedOpen Access
498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01
Regular and Young Investigator Award Abstracts·2021· 8 citedOpen Access
433 A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04
Regular and Young Investigator Award Abstracts·2021Open Access
Abstract 1721: TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes anti-tumor immunity and favorable safety profile following systemic administration in preclinical models
Cancer Research·2021· 12 cited
Anti-GD2 antibody disrupts GD2:Siglec-7 interactions and synergizes with CD47 blockade to mediate tumor eradication
2021· 2 cited
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity
Journal of Hematology & Oncology·2020· 69 citedOpen Access
ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
Blood·2020· 25 cited
ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies
Blood·2020· 5 cited
615 Targeted immune cell activation by systemic delivery of toll-like receptor 9 agonist antibody conjugates induce potent anti-tumor immunity
Regular and Young Investigator Award Abstracts·2020Open Access
A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.
Journal of Clinical Oncology·2020· 19 cited
A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
Blood·2019· 25 cited
Abstract 562: Antibodies to Sirpα enhance innate and adaptive immune responses to promote anti-tumor activity
Cancer Research·2019
Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα
mAbs·2019· 48 citedOpen Access
A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.
Journal of Clinical Oncology·2019· 18 cited
ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile
PLoS ONE·2018· 164 citedOpen Access
A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.
Journal of Clinical Oncology·2018· 20 cited
Epitope Mapping Using Yeast Display and Next Generation Sequencing
Methods in molecular biology·2018· 12 cited
page 1 of 2Next →

Frequent Co-authors

Hong Wan(15), Tracy C. Kuo(12), Emma Sangalang(10), Ons Harrabi(10), Sophia Randolph(10), Arvind Rajpal(9), Amy Chen(9), Janet Sim(9), Javier Chaparro‐Riggers(7), Pavel Strop(7), Laura V. Doyle(7), Philip Fanning(7), Feng Jin(7), Bora Han(6), Nehal J. Lakhani(6), Sangeetha Bollini(5), Steven E. Kauder(5), Davide Foletti(5), Purnima Sundar(5), Steven J. Pitts(5)